Tapinarof

Generic Name: Tapinarof

Brand Names: Vtama

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈O_₂

CAS Number: 79338-84-4

Unique Ingredient Identifier: 84HW7D0V04

Background: Tapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis. It is available as a topical cream to be applied to the affected area once daily. Tapiranof was first discovered as a metabolite (3,5-dihydroxy-4-isopropylstilbene) produced in Photorhabdus luminescens, a gram-negative bacillus that lives symbiotically with the Heterorhabditis nematodes. In 1959, it was noticed that Heterorhabditis with a high amount of 3,5-dihydroxy-4-isopropylstilbene did not putrefy once dead, thus suggesting its potential anti-inflammatory activity.

Tapinarof received initial approval from the FDA in 2022.

Indication: Tapinarof is indicated for the topical treatment of plaque psoriasis in adults.

Associated Conditions: Psoriasis Vulgaris (Plaque Psoriasis)

Clinical Trials

Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

Phase 3

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: tapinarof cream, 1%

First Posted Date: 2021-12-29

Last Posted Date: 2024-12-10

Lead Sponsor: Dermavant Sciences, Inc.

Target Recruit Count: 100

Registration Number: NCT05172726

Locations: 🇨🇦
Dermavant Clinical Trials, Oshawa, Ontario, Canada
🇨🇦
Dermavant Clinical Site, Montréal, Quebec, Canada

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Tapinarof cream, 1%

First Posted Date: 2021-12-03

Last Posted Date: 2024-07-08

Lead Sponsor: Dermavant Sciences, Inc.

Target Recruit Count: 728

Registration Number: NCT05142774

Locations: 🇺🇸
Dermavant lnvestigative Site, Greenville, South Carolina, United States
🇨🇦
Dermavant Investigative Site, Montréal, Quebec, Canada

Phase IV Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Psoriasis in Adults

Phase 4

Recruiting

Conditions: Psoriasis

Interventions: Drug: Benvitimod

First Posted Date: 2021-10-01

Last Posted Date: 2021-10-01

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 2000

Registration Number: NCT05064748

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: vehicle cream
Drug: tapinarof cream, 1%

First Posted Date: 2021-09-02

Last Posted Date: 2024-07-08

Lead Sponsor: Dermavant Sciences, Inc.

Target Recruit Count: 406

Registration Number: NCT05032859

Locations: 🇺🇸
Dermanvant Investigative Site, Brooklyn, New York, United States
🇨🇦
Dermavant Investigative Site, Windsor, Ontario, Canada

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Vehicle cream
Drug: tapinarof cream, 1%

First Posted Date: 2021-08-20

Last Posted Date: 2024-07-08

Lead Sponsor: Dermavant Sciences, Inc.

Target Recruit Count: 407

Registration Number: NCT05014568

Locations: 🇨🇦
Dermavant Investigative Site, Montréal, Quebec, Canada

Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: tapinarof cream, 1%

First Posted Date: 2019-08-12

Last Posted Date: 2022-09-29

Lead Sponsor: Dermavant Sciences GmbH

Target Recruit Count: 763

Registration Number: NCT04053387

Locations: 🇨🇦
Dermavant Investigative Site, Montréal, Quebec, Canada
🇨🇦
Dermavant Clinical Site, Markham, Ontario, Canada
🇺🇸
Dermavant Investigational Site, Detroit, Michigan, United States

and more 1 locations